Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation.

Therapeutic drug monitoring - 1 Aug 2026

Vidal-Alabró Anna, Fontova Pere, Mohammed Ali Zeyar, Fernández-Alarcón Beatriz, Cerezo Gema, Melilli Edoardo, Montero Nuria, Coloma Ana, Manonelles Anna, Favà Alexandre, Codina Sergi, Couceiro Carlos, Oliveras Laia, Torras Joan, Grinyó Josep M, Cruzado Josep M, Colom Helena, Lloberas Nuria

Abstract excerpt

BACKGROUND: Tacrolimus is the most commonly used immunosuppressant drug in solid organ transplant recipients. Different formulations of tacrolimus have distinct pharmacokinetic profiles due to differences in absorption and elimination. This study aimed to investigate the influence of CYP3A5 polymorphisms on tacrolimus exposure after conversion from immediate-release tacrolimus (Tac-IR) to prolonged-release...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Delayed-Action Preparations

Share to Dose-Response Relationship, Drug

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Polymorphism, Genetic

Share to Tacrolimus

Source

Identifiers

PMID: 41358630
DOI: 10.1097/FTD.0000000000001411

Genes

CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation.PMID 41358630Read ↗

Optimizing Dose Conversion From IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudySemantic proximity Read ↗

Effect of <em>CYP3A5</em> Polymorphism on Liver Function and Tacrolimus Pharmacokinetics after Conversion to a Once-Daily Tacrolimus Formulation in Stable Liver Transplant PatientsSemantic proximity Read ↗

Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.Semantic proximity Read ↗

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant RecipientsSemantic proximity Read ↗

Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.Semantic proximity Read ↗

Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.Semantic proximity Read ↗

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentSemantic proximity Read ↗

Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation.Semantic proximity Read ↗

Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review.Semantic proximity Read ↗

Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.Semantic proximity Read ↗

Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.Semantic proximity Read ↗

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.